Medication Monitor

Generic Name (Trade Name—Company)
October 31, 2019

Teriparatide injection

FDA approves teriparatide injection for osteoporosis

FDA approved teriparatide injection, a therapeutic equivalent candidate of Forteo, to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and to treat men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.

In a statement, Pfenex said its commercial partner, Alvogen, is expected to launch the drug upon an FDA decision on the therapeutic equivalence rating.